Stocktoria
BeyondSpring Inc. BYSI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-03-09
BeyondSpring Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.4M | $1.4M |
| R&D expense | $4.4M | $2.6M | $7.3M | $25.6M | $36.9M |
| SG&A expense | $4.6M | $6.1M | $7.8M | $13.0M | $30.7M |
| Operating income | -$8.9M | -$8.8M | -$15.1M | -$37.2M | -$66.2M |
| Interest expense | — | — | — | $17,000 | $87,000 |
| Income tax | $90,000 | $96,000 | -$92,000 | $163,000 | $3.6M |
| Net income | -$1.0M | -$11.1M | -$21.0M | -$33.3M | -$64.2M |
| Operating cash flow | -$19.8M | -$16.4M | -$16.5M | -$27.5M | -$47.2M |
| Free cash flow | -$19.8M | -$16.7M | -$16.6M | -$27.5M | -$50.1M |
| Cash & equivalents | $7.8M | $2.9M | $5.4M | $34.4M | $41.6M |
| Total assets | $25.9M | $34.3M | $24.8M | $46.2M | $81.6M |
| Total liabilities | $49.9M | $48.6M | $48.3M | $49.2M | $55.3M |
| Shareholders' equity | -$32.2M | -$32.9M | -$35.3M | -$14.1M | $26.7M |
Source: SEC EDGAR filings · CIK 0001677940 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.